Skip to main content
eScholarship
Open Access Publications from the University of California

Scholarly Works (3 results)

  • Article
  • Peer Reviewed
Dermatology Online Journal, Volume 23, Issue 8 (2017)

Background/Study Aim: A multispectral digital skin lesion analysis (MSDSLA) device has proven to be sensitive and specific for malignant melanoma (MM) detection by dermatologists and may have other useful applications. This study aimed to develop and test objective quantitative Asymmetry, Border irregularity, Color, and Diameter (qABCD) parameters for MSDSLA and correlate them with the presence of clinical ABCD features to aid the decision to biopsy a suspicious pigmented skin lesions (PSLs).

Methods: 1632 benign and malignant [175 MM/High Grade Dysplastic Nevi (HGDN)] were evaluated for their qABCD parameters. Quantitative characteristics were correlated with the presence of clinical ABCD features identified by independent dermatologists.

Results: qA, qB, qC, and qD had correlations of 78%, 73%, 76%, and 86%, respectively, for non-MM/HGDN lesions. The correlations for qA, qB, qC, and qD for MM/HGDN lesions was 86.3%, 83%, 89%, and 89%, respectively. All repeatability parameters were statistically significant.

Conclusions: This study demonstrates qABCD values are repeatable and strongly correlate with the clinical ABCD features. qABCD characteristics provide an additional objective and reliable means of identifying PSLs that need further evaluation to rule out MM and, in combination with the clinical ABCDs, may allow for improved assessment when evaluating the malignant potential of PSLs.

    Cover page: Quantitative ABCD parameters measured by a multispectral digital skin lesion analysis device for evaluation of suspicious pigmented skin lesions strongly correlate with clinical ABCD observationsCreative Commons 'BY-NC-ND' version 4.0 license
    • Article
    • Peer Reviewed
    Dermatology Online Journal, Volume 25, Issue 6 (2019)
    The revised version of the article corrected Figure 2. This change appears in the revised online PDF copy of this article.
      Cover page: Corrigendum: Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month followup of negative test results and utility data from a large US registry studyCreative Commons 'BY-NC-ND' version 4.0 license
      • Article
      • Peer Reviewed
      Dermatology Online Journal, Volume 25, Issue 5 (2019)
      The Pigmented Lesion Assay (PLA, sensitivity 91-95%, specificity 69-91%, negative predictive value ?99%) is a commercially available, non-invasive gene expression test that helps dermatologists guide pigmented lesion management decisions and rule out melanoma. Earlier studies have demonstrated high clinical utility and no missed melanomas in a 3-6-month follow-up period. We undertook the current investigations to provide 12-month follow-up data on PLA(-) tests, and to further confirm utility. A 12-month chart review follow-up of 734 pigmented lesions that had negative PLA results from 5 US dermatology centers was performed. Thirteen of these lesions (1.8%) were biopsied in the follow-up period and submitted for histopathologic review. None of the lesions biopsied had a histopathologic diagnosis of melanoma. The test's utility was studied further in a registry (N=1575, 40 US dermatology offices, 62 participating providers), which demonstrated that 99.9% of PLA(-) lesions were clinically monitored, thereby avoiding a surgical procedure, and 96.5% of all PLA(+) lesions were appropriately biopsied, most commonly with a tangential shave. This long-term follow-up study confirms the PLA's high negative predictive value and high utility in helping guide the management of pigmented lesions to avoid unnecessary surgical procedures.
        Cover page: Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry studyCreative Commons 'BY-NC-ND' version 4.0 license
        Top